PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling
about
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective mannerDual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal CancersImpact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotypeDiscovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.Systematic identification of combinatorial drivers and targets in cancer cell linesDecoupling polarization of the Golgi apparatus and GM1 in the plasma membraneCaffeic acid derivatives inhibit the growth of colon cancer: involvement of the PI3-K/Akt and AMPK signaling pathwaysSelective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance.Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells.RAS Interaction with PI3K: More Than Just Another Effector PathwayInhibition of fatty acid synthase induces pro-survival Akt and ERK signaling in K-Ras-driven cancer cells.Akt and ERK control the proliferative response of mammary epithelial cells to the growth factors IGF-1 and EGF through the cell cycle inhibitor p57Kip2.Antitumor activity in RAS-driven tumors by blocking AKT and MEK.Resibufogenin Induces G1-Phase Arrest through the Proteasomal Degradation of Cyclin D1 in Human Malignant Tumor CellsA novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor.Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33.Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancerSensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.Prx I suppresses K-ras-driven lung tumorigenesis by opposing redox-sensitive ERK/cyclin D1 pathway.A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilitiesMutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.Requirement for interaction of PI3-kinase p110α with RAS in lung tumor maintenance.MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.Network quantification of EGFR signaling unveils potential for targeted combination therapy.mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.SmgGDS-558 regulates the cell cycle in pancreatic, non-small cell lung, and breast cancers.Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.The ERK Cascade: Distinct Functions within Various Subcellular Organelles.The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches.Mechanisms of acquired resistance to ERK1/2 pathway inhibitors.Pancreatic cancer stem cells: regulatory networks in the tumor microenvironment and targeted therapy.Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer.Targeting the Ras-ERK pathway in pancreatic adenocarcinoma.PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.
P2860
Q21629049-BFB0A59E-DC8E-4638-AA5D-6993EC9EF102Q26781362-1536DAEC-0EF6-4D3B-A280-BE3E73D25A0FQ27334924-A11C1A19-6D13-469B-9AE3-35981C1F2FF9Q27711042-A3386525-F352-4A88-A1BA-DEE3F8E9E38DQ27851674-903B81FC-0574-438A-B94F-E0C908C895B6Q28486051-259611AB-0C21-4D28-A06D-0E7ED3F7D8A1Q28535581-E50FD46B-F8FD-4ABC-B341-6A55B925A3E1Q33800268-0F857E97-F1C4-48E9-A5B7-4F44C6EE6F75Q33955186-C2CB8140-5967-400B-8133-4C3BA0C5A917Q34036069-8B303FF7-B592-4444-BA02-8DF51EC2F00CQ34202692-B43628EE-4285-46AD-9020-D363770859C7Q34223118-250C72E7-0952-4266-A444-62F3AFDB4C7AQ34241184-F921EF98-23D6-4BA9-B14E-0F19B70BA2EEQ35103514-D792B0DF-ECBD-43CD-B297-5D54A7126A34Q35677008-BC940B31-D427-4623-9193-B7140F277E26Q35798191-E9C39DDF-76D4-4EA1-88DE-F73A82FFD995Q35894216-B0014D81-DF85-4C62-913B-76A125414441Q35951620-4F636A86-630D-47FF-A6F8-847B891B971FQ36471372-B4BC6496-771D-4BCF-983B-90387BB5D90DQ36645788-A4DC2000-DC81-4149-AEE8-F343E1E6DEEBQ36906305-0D3871F3-C38C-4DEE-91FA-3E283D182316Q36991367-851B8900-4F64-4E0B-BE4C-D364D1D9E17CQ37279495-4CA07903-B008-425B-ADBA-2C6E01699EC2Q37301530-8D0D9399-FFE2-4758-A1CD-793B3D0AFA54Q37303694-703A04D7-4DF4-4B2B-9CAA-F6ADE2EDB762Q37381179-810C5117-BE2D-4EA1-8C24-5C76D02EF1F0Q37457602-6877B434-102B-440E-AD42-8E12F77AC734Q37660498-2A2E249D-CF16-464E-8F3E-3063BB683406Q37680565-609F2C14-BC03-45AD-B0C9-B974B8651A93Q37698902-69715E56-4539-4A53-AE39-F874E2004CD4Q37837732-7B471BEB-5591-4BB5-97C7-13FFED1352ECQ37865381-0E3C5A77-AA8C-4E36-AB73-BBEE6CAABA66Q37903694-E50AF96C-4DCB-457B-8297-04473B350551Q37945533-C49D6D37-32F9-4A00-A5F7-A230B150EC43Q37996420-5AE9464D-C6FC-4D59-93F5-EF83B208CA31Q38007869-55F1A72B-315F-4B3D-BAA0-206E0CC4974EQ38033459-0046B47E-262C-495A-80E2-5644B09DF1F8Q38042938-CF96C543-AF77-4970-90DF-867B1F365248Q38053855-675C74AF-D25E-4CE6-A681-421E5D0477FCQ38084846-119A79EE-FFD4-40C2-A18A-C74FE9B6A6F1
P2860
PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
PIK3CA mutation uncouples tumo ...... /ERK and mutant KRAS signaling
@ast
PIK3CA mutation uncouples tumo ...... /ERK and mutant KRAS signaling
@en
type
label
PIK3CA mutation uncouples tumo ...... /ERK and mutant KRAS signaling
@ast
PIK3CA mutation uncouples tumo ...... /ERK and mutant KRAS signaling
@en
prefLabel
PIK3CA mutation uncouples tumo ...... /ERK and mutant KRAS signaling
@ast
PIK3CA mutation uncouples tumo ...... /ERK and mutant KRAS signaling
@en
P2093
P2860
P1433
P1476
PIK3CA mutation uncouples tumo ...... /ERK and mutant KRAS signaling
@en
P2093
David B Solit
Ensar Halilovic
Neal Rosen
Qing-Bai She
Raymond Pagliarini
William R Sellers
P2860
P304
P356
10.1158/0008-5472.CAN-10-0409
P407
P577
2010-08-10T00:00:00Z